Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Change in Accured Expenses (2023 - 2025)

Historic Change in Accured Expenses for Tonix Pharmaceuticals Holding (TNXP) over the last 3 years, with Q3 2025 value amounting to $1.2 million.

  • Tonix Pharmaceuticals Holding's Change in Accured Expenses rose 16315.79% to $1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.2 million, marking a year-over-year decrease of 2106.69%. This contributed to the annual value of $1.2 million for FY2024, which is 3337.07% down from last year.
  • Per Tonix Pharmaceuticals Holding's latest filing, its Change in Accured Expenses stood at $1.2 million for Q3 2025, which was up 16315.79% from $3.4 million recorded in Q2 2025.
  • In the past 5 years, Tonix Pharmaceuticals Holding's Change in Accured Expenses ranged from a high of $4.4 million in Q4 2023 and a low of -$3.0 million during Q1 2023
  • For the 3-year period, Tonix Pharmaceuticals Holding's Change in Accured Expenses averaged around $421727.3, with its median value being $913000.0 (2024).
  • The largest annual percentage gain for Tonix Pharmaceuticals Holding's Change in Accured Expenses in the last 5 years was 26834.61% (2025), contrasted with its biggest fall of 6895.76% (2025).
  • Over the past 3 years, Tonix Pharmaceuticals Holding's Change in Accured Expenses (Quarter) stood at $4.4 million in 2023, then crashed by 65.02% to $1.5 million in 2024, then fell by 19.25% to $1.2 million in 2025.
  • Its last three reported values are $1.2 million in Q3 2025, $3.4 million for Q2 2025, and -$2.9 million during Q1 2025.